The Klotho level inTg-Kl-CKD mice was lower thanTg-Kl-Shammice but still equivalent to that ofWT-Shammice (Figure 2A and Supplemental Figure 2A).Tg-Klmice have higher plasma Klotho levels36and more organs expressing Klotho protein.9In the kidneys ofTg-Klmice, almost all of the renal structures express Klotho protein (Supplemental Figure 2B). == Table 2. mineralization induced by high phosphate and preserved differentiation in vascular smooth muscle cells. In summary, Klotho is an early biomarker for CKD, and Klotho deficiency contributes to soft-tissue calcification in CKD. Klotho ameliorates vascular calcification by enhancing phosphaturia, preserving glomerular filtration, and directly inhibiting phosphate uptake by vascular smooth muscle. Replacement of Klotho may have therapeutic potential for CKD. The high cardiovascular mortality in patients with chronic kidney disease (CKD) is closely associated with vascular calcification (VC).1,2Risk factors for VC include hypertension, hyperlipidemia, diabetes, plasma phosphate, homocysteine, and osteoprotegerin.3,4Defects in endogenous anti-calcification factors such as matrix Gla protein, osteoprotegerin, carbonic anhydrase isoenzyme II, fibrillin-1, fetuin-A, fibroblast growth factor 23, and Klotho may play an important role in this dire complication of CKD. 510High serum phosphate is associated with significantly increased risk for death.11Treatment with phosphorus binders improves survival of hemodialysis patients compared with no treatment with matched baseline serum phosphate levels.12 Early diagnosis and treatment is important to retard the progression of CKD. Most biomarkers in current clinical use are not early or sensitive enough.1316The need to find a sensitive and early biomarker is of paramount importance for early diagnosis and intervention. Various strategies have been devised to slow progression of renal disease12,17,18with varying effectiveness.19We are in dire need of additional fresh agents in preventing the progression of CKD and in ameliorating VC. Klothowas originally identified as an ageing suppressor.9Its gene product is a single-pass transmembrane protein9,20that functions like TPO agonist 1 a coreceptor for fibroblast growth element (FGF) 23.2124Klotho is expressed widely, but its level is highest in the kidney.25,26Klotho is also secreted into the cerebrospinal fluid, blood, and urine25,27by ectodomain shedding mediated by membrane-anchored proteases.28,29Secreted Klotho functions in an endocrine fashion as an enzyme or possibly a hormone. Klotho deficiency in rodents prospects to a syndrome of premature ageing where ectopic smooth tissue calcification is definitely a notable feature.9Overexpression of Klotho TPO agonist 1 rescues TPO agonist 1 the Klotho-deficient phenotype including ectopic calcification, suggesting that Klotho may be an inhibitor of ectopic calcification.9 Because of the features common to both human being CKD and murine experimental Klotho deficiency (Kl/), we postulate Mouse monoclonal to FOXA2 that Klotho deficiency may be responsible for the VC in CKD. The literature gives suggestive but limited evidence for any pathogenic part of Klotho in CKD. Renal Klotho mRNA is lower inside a five-sixths nephrectomy model of CKD and in human being nephrectomy samples from end-stage sclerotic kidneys.3032A moderate amelioration of proteinuria and renal function was observed when Klotho was overexpressed genetically inside a chronic glomerulonephritis magic size33or via viral delivery inside a chronic angiotension II34and a spontaneous hypertension magic size.35 We will test three hypotheses: (1) CKD is a state of Klotho deficiency; (2) low Klotho is TPO agonist 1 an early marker of CKD; and (3) Klotho deficiency contributes to VC and Klotho alternative ameliorates CKD via multiple mechanisms. == RESULTS == == CKD Is definitely a State of Klotho Deficiency == The pattern of calcification of smooth cells in CKD is definitely indistinguishable from that seen in Klotho deficiency in rodents.3,9,36,37We found out similar raises in tissue calcium content material inKl/and CKD animals (Number 1, A and B). We next asked whether CKD is definitely a state of endocrine Klotho deficiency. End-stage CKD individuals31and animals30,33have reduced Klotho in kidneys, but there is no data on blood or urine Klotho in CKD. Klotho was undetectable in homozygous Klotho deficiency (Kl/) (Number 1C) and was notably decreased in kidney and barely detectable in the blood and urine of CKD mice (Number 1C), indicating that CKD is definitely a state of pan deficiency of Klotho. Because of the lack of a reliable assay for human being plasma Klotho at the time of the study, we measured urinary Klotho in CKD.